CTCorrado Tarella

Corrado Tarella

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Corrado Tarella has a total of 147 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Repeated courses of sequential venetoclax and donor lymphocyte infusions in a patient with relapsed high-risk myelodysplasia following allogeneic stem cell transplantation: a case report

    by Federica Gigli, Valentina Fabiola Sangiorgio, Valentina Tabanelli, Giuliana Gregato, Francesco Bertolini, Alessio Maria Edoardo Maraglino, Simona Sammassimo, Rocco Pastano, Enrico Derenzini, Corrado Tarella

    Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents the only potentially curative therapy in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). However, a considerable proportion of patients experience post-transplant relapse, a condition associated with relevant morbidity and an overall dismal prognosis. In this context, the administration of donor lymphocyte infusion (DLI) has been historically used to exploit the graft- versus -leukemia (GvL) effect of allo-HSCT. More recently, hypomethylating agents (HMAs) and venetoclax (VEN), a combination used in first-line/relapsed AML, has also been applied, alone or in association with DLI, for post-transplant relapses, with some encouraging results. Despite several reports showing the feasibility and efficacy of the HMA-VEN combination, the long-term outcome is still poor and the management of AML relapse following allo-HSCT remains unsatisfactory. Thus far, the ideal treatment has not been defined. Case description: We report here the successful treatment of a patient with high-risk MDS and relapse onset following allo-HSCT. The patient was started on salvage treatment with azacitidine (AZA) and low-dose VEN. Surprisingly, bone marrow cellularity was restored, with rapid improvement of the hematological parameters and recovery of full chimerism as well after a single initial course of AZA/VEN. Two additional courses of AZA/VEN supplemented with DLI were delivered, and then the patient was placed on a maintenance treatment with the sequence of VEN single agent tightly followed by DLI. Six courses of combined VEN/DLI were delivered at 3-month intervals. This innovative strategy proved to be effective in terms of disease control, absence of infectious complications, and quality of life. The patient is presently alive and well in continuous complete remission (CR) 24 months since disease recurrence. The details of his recent clinical history are reported here. Conclusion: Recurrent courses of VEN in combination with DLI may be exploited for CR maintenance in patients with MDS/AML managed for disease recurrence after allo-HSCT.

  • Open Access

    Telomere Length Abnormality: Investigating Approaches and Correlations with Cancer, Bone Marrow Failure and Hematological Malignancies

    by Corrado Tarella, Dario Ferrero, Maria Beatriz Herrera Sanchez, Alessia Rita Canestrale, Sharad Kholia, Lorenzo Silengo, Enrico Derenzini, Irene Ricca

    Proper telomere maintenance is crucial for ensuring healthy cellular function. Telomeres have a tendency to reduce in length with cellular aging. Moreover several factors may promote telomere attrition. Other conditions, primarily due to genetic and inherited origins, can be characterized by unusually long telomeres. Both shortening and elongation of telomere length (TL) may lead to increased risk of cancer occurrence or cancer progression. Additionally, some hematopoietic dysfunctions may also be associated with telomere abnormalities. This review is aimed to describe and discuss main aspects of TL, in relation to carcinogenesis. The initial section describes main current methods for TL assessment, since the accurate and reliable TL measurements is a crucial issue in TL research. The various studies describing the association between TL and cancer risk are then reported and critically illustrated, with special interest on TL shortening in hematological malignancies, as well as in some peculiar non-malignant dysfunctions. Hence, a systematic analysis of the broad contribution of TL to cancer development is extensively appraised.


  • Open Access

    Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials

    by Simonetta Viviani, Chiara Pavoni, Sally F. Barrington, Luca Guerra, Heiko Schöder, Peter Johnson, Amy A. Kirkwood, Deborah M. Stephens, Jonathan W. Friedberg, Stephane Chauvie, et al.

    PET after 2 ABVD cycles (PET-2) is widely adopted to select patients with classical Hodgkin lymphoma (cHL), who might benefit from intensifying or de-escalating therapy. Prolonged progression-free survival (PFS) has been reported in PET-2 positive patients switched to escalated BEACOPP (eBEACOPP) or BEACOPP-14. Nevertheless, the subgroup of patients with a PET-2 scored 5 according to Deauville score (PET-2 DS5) are known to poorly benefit from treatment intensification. To elucidate PET-2 DS5 outcome along with possible predictive factors of response to intensification, a pooled analysis from three multicenter trials, GITIL/FIL HD0607, RATHL, and SWOG S0816, was conducted. PFS and overall survival (OS) were assessed after 41-month median follow-up, the prognostic value of clinical, laboratory, and PET parameters at diagnosis was evaluated. Among 2231 patients, 136 (6%) PET-2 DS5 patients were identified. Their 3-year PFS was 32% (95% CI, 25–42), while the 3-year OS was 82% (95% CI, 75–89). In multivariate analysis low lymphocyte (< 600/mm3) counts were adversely associated with PFS, whereas age ≥ 45 years and leukocytes cells count 80% survival at 3 years, thus excluding a real disease refractoriness. Few distinct parameters may have specific prediction for PFS or OS.


  • Open Access

    Long-Term Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: An Italian Multicenter Collaborative Study

    by Corrado Tarella, Simona Sammassimo, Samuele Frassoni, Alida Dominietto, Raffaella Cerretti, Maria Caterina Micò, Rocco Pastano, Martina Pennisi, Maria Chiara Di Chio, Chiara Ghiggi, et al.


  • Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia

    by Cecilia Restelli, Marco Ruella, Luca Paruzzo, Corrado Tarella, Pier Giuseppe Pelicci, Emanuela Colombo

    Despite advancements, acute myeloid leukemia (AML) remains unconquered by current therapies. Evidence of immune evasion during AML progression, such as HLA loss and T-cell exhaustion, suggests that antileukemic immune responses contribute to disease control and could be harnessed by immunotherapy. In this review, we discuss a spectrum of AML immunotherapy targets, encompassing cancer cell-intrinsic and surface antigens as well as targeting in the leukemic milieu, and how they can be tailored for personalized approaches. These targets are overviewed across major immunotherapy modalities applied to AML: immune checkpoint inhibitors, antibody–drug conjugates, therapeutic vaccines, bispecific/trispecific antibodies, and chimeric antigen receptor (CAR)-T and CAR-NK cells. Significance: Immune therapies in AML treatment show evolving promise. Ongoing research aims to customize approaches for varied patient profiles and clinical scenarios. This review covers immune surveillance mechanisms, therapy options like checkpoint inhibitors, antibodies, CAR-T/NK cells, and vaccines, as well as resistance mechanisms and microenvironment considerations.


  • Open Access

    Long telomeres at baseline and male sex are main determinants of telomere loss following chemotherapy exposure in lymphoma patients

    by Enrico Derenzini, Angela Gueli, Alessandra Risso, Riccardo Bruna, Daniela Gottardi, Alessandro Cignetti, Stefano Pileri, Enrico V. Avvedimento, Corrado Tarella

    Although chemotherapy (CHT) exposure is an established cause of telomere attrition, determinants of telomere length (TL) dynamics after chemotherapy are poorly defined. In this study, we analyzed granulocyte telomere dynamics in 34 adult lymphoma patients undergoing first-line CHT. TL was measured by southern blot at each CHT cycle and after 1 year from CHT completion. Median age was 59 yrs (range 22-77). Median number of CHT cycles was 6 (range 3-6). The majority of patients (79%, n = 27) experienced TL shortening following CHT exposure. Mean telomere loss was 673 base pairs (bp) by cycle 6. Telomere shortening was an early event as 87% of the total telomere loss (mean 586 bp) occurred by the end of cycle 3, with no significant recovery after 1 year. A significant correlation was observed between baseline TL and total or fractional telomere loss (p < 0.001), with telomere shortening by cycle 3 observed predominantly in male patients with long telomeres at pre-treatment evaluation. Stratifying the analysis by gender and age only young women (<51 years of age) did not show significant telomere shortening following chemotherapy exposure. These findings indicate that gender and baseline TL are major determinants of TL dynamics following chemotherapy exposure in lymphoma patients.


  • Advances in therapeutic strategies for primary CNS B-cell lymphomas

    by Safaa Ramadan, Tommaso Radice, Ahmed Ismail, Stefano Fiori, Corrado Tarella

    Primary CNS lymphoma (PCNSL) has traditionally been treated with induction HD-MTX-based chemotherapy, followed by consolidation whole-brain radiotherapy. However, this approach is associated with s...


  • Open Access

    CD19-Mediated DNA Damage Boost in Lymphoma Cells Treated with Loncastuximab Tesirine in Combination with PARP Inhibitors

    by Stefania Fusani, Alessandra Rossi, Saveria Mazzara, Elena Baiardi, Francesca Zammarchi, Patrick H van Berkel, Stefano A Pileri, Corrado Tarella, Enrico Derenzini

    Overexpression of the MYC oncogene is a frequent feature of diffuse large B-cell lymphoma (DLBCL) being associated with poor prognosis following standard R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) chemoimmunotherapy. Since MYC expression is associated with overactivation of the DNA damage response (DDR), targeting DDR pathways with selective small molecule inhibitors could be a promising strategy to circumvent the inherent resistance to exogenous DNA damage proper of MYC-positive DLBCL. Loncastuximab tesirine-lpyl (here abbreviated as Lonca) is an antibody-drug conjugate (ADC) composed of a humanized anti-CD19 antibody conjugated to a potent DNA-crosslinking pyrrolobenzodiazepine dimer toxin. We hypothesized that DDR inhibition could increase the efficacy of Lonca by selectively enhancing DNA damage induction in B-cell lymphoma cells. In a preliminary analysis of a publicly available dataset (Sha et al. J Clin Oncol 2019), we found a significant correlation between MYC and PARP1 gene expression levels, with higher PARP1 levels observed in DLBCL samples characterized by high MYC expression. Following this observation, with the aim of developing a treatment strategy for MYC-positive DLBCL, we tested the in vitro activity of 3 FDA-approved PARP inhibitors (Olaparib, Rucaparib, Talazoparib) in a panel of 13 CD19+ DLBCL cell lines (7 with MYC rearrangements). Cytotoxicity was evaluated with Cell Titer Glo assay (CTG), and all compounds showed anti-proliferative activity in a dose and time-dependent manner. Compared with Olaparib and Rucaparib, Talazoparib (Talazo) showed more potent in vitro activity as single agent, with IC50 values in the submicromolar range (100-200 nM at 5 days) observed in most cell lines, in line with its increased PARP trapping capacity. Of note, the BRCA-mutated cell line DOHH2 was the most sensitive to all 3 PARPi, in line with the known synthetic lethal interaction between BRCA mutations and PARP inhibition. Lonca showed significant cytotoxic activity in 10 of 13 cell lines, which were sensitive in the same range of clinically achievable concentrations, with IC50 values ≤ 1 ng/ml at 5 days; conversely, the B12 isotype control ADC was completely ineffective. Interestingly, BRCA-mutated DOHH2 cells were highly sensitive to single agent Lonca, and those cell lines that were resistant to Lonca (SUDHL-2, Pfeiffer, SUDHL-10) displayed also reduced sensitivity to Talazo. The combination of Talazo and Lonca produced enhanced anti-proliferative effects, with strong synergism (evaluated by combination index analysis) observed in most cell lines. Notably, those cell lines resistant to both compounds as single agents became sensitive to the combination. To investigate the mechanisms underlying these synergistic interactions, we performed 2D-cell cycle analysis by flow cytometry with bromodeoxyuridine (BrdU) and propidium iodide staining at different time points (24h-72h-5days). While single agent treatments predominantly increased the fraction of cells in G2/M phase, the combination of Talazo and Lonca clearly increased the fraction of cells in the BrdU-negative S phase of the cell cycle, (which represents cells that are not actively synthetizing DNA, S-), thus suggesting a mechanistic interaction between the two drugs (Fig. 1). Treatment with the Lonca/Talazo combination induced cell death (as measured by trypan blue assay or SubG1 fraction of the cell cycle), in the absence of significant caspase cleavage. Western blot assay showed enhanced induction of the DNA damage marker γH2AX in cells treated with the combination after 24 hours of incubation. In line with this, alkaline Comet assay confirmed enhanced DNA damage induction after 24h of combinational treatment as compared to single agents, thus confirming that DDR inhibition significantly increases the amount of DNA damage induced by Lonca. Comet assay performed on peripheral blood CD19+ B cells from healthy donors following ex-vivo treatment with Talazo, Lonca or the combination showed similar DNA damage induction patterns. Importantly, no DNA damage could be detected in CD3+ T-cells from the same healthy donors. In conclusion, these data indicate that PARP inhibition significantly enhances the efficacy of Lonca in in vitro DLBCL models, providing the rationale to develop precision therapy strategies aimed at boosting DNA damage induction in neoplastic B-cells.


  • Open Access

    Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma

    by Alessandra Rossi, Stefania Orecchioni, Paolo Falvo, Valentina Tabanelli, Elena Baiardi, Claudio Agostinelli, Federica Melle, Giovanna Motta, Angelica Calleri, Stefano Fiori, et al.

    Standard chemotherapies for diffuse large B-cell lymphoma (DLBCL), based on the induction of exogenous DNA damage and oxidative stress, are often less effective in the presence of increased MYC and BCL-2 levels, especially in the case of double hit (DH) lymphomas harboring rearrangements of the MYC and BCL-2 oncogenes, which enrich for a patient’s population characterized by refractoriness to anthracycline-based chemotherapy. Here we hypothesized that adaptive mechanisms to MYC-induced replicative and oxidative stress, consisting in DNA damage response (DDR) activation and BCL-2 overexpression, could represent the biologic basis of the poor prognosis and chemoresistance observed in MYC/BCL-2-positive lymphoma. We first integrated targeted gene expression profiling (T-GEP), fluorescence in situ hybridization (FISH) analysis, and characterization of replicative and oxidative stress biomarkers in two independent DLBCL cohorts. The presence of oxidative DNA damage biomarkers identified a poor prognosis double expresser (DE)-DLBCL subset, characterized by relatively higher BCL-2 gene expression levels and enrichment for DH lymphomas. Based on these findings, we tested therapeutic strategies based on combined DDR and BCL-2 inhibition, confirming efficacy and synergistic interactions in in vitro and in vivo DH-DLBCL models. These data provide the rationale for precision-therapy strategies based on combined DDR and BCL-2 inhibition in DH or DE-DLBCL.


  • Open Access

    Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term

    by Sergio Cortelazzo, Michael Mian, Andrea Evangelista, Liliana Devizzi, Paolo Corradini, Michele Magni, Marco Ladetto, Simone Ferrero, Andrea Rossi, Anna Maria Barbui, et al.